Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro

TH Open : Companion Journal to Thrombosis and Haemostasis
Masahiro TakeyamaDebra Pollard

Abstract

Objective  Turoctocog alfa is a recombinant factor VIII (rFVIII) for the prevention and treatment of bleeding in patients with hemophilia A, including those undergoing surgery and invasive medical procedures. This in vitro study evaluated the physical and chemical stability of turoctocog alfa during continuous infusion (CI) over 24 hours at 30°C. Materials and Methods  The study was performed at 30°C ( ± 2°C). A CI system with pump speed set at either 0.6 or 1.5 mL/h was used to evaluate the stability of three turoctocog alfa strengths (500, 1,000, and 3,000 IU), equating to doses of 1.1 to 16.1 IU/h per kilogram of body weight. The following parameters were evaluated at selected time points between 0 and 24 hours: appearance of solution, clarity, pH, potency, purity, content, total high molecular weight proteins (HMWPs), and oxidized rFVIII. Results  The mean potency of turoctocog alfa was maintained within the predefined acceptance criteria during CI for both pump speeds with all three strengths at 6, 12, or 24 hours (500 IU: ≥484 IU/vial; 1,000 IU: ≥1,014 IU/vial; and 3,000 IU: ≥3,029 IU/vial). Furthermore, the appearance of solution, clarity, pH, purity, content of turoctocog alfa, total HMWP, and oxidized forms were also w...Continue Reading

References

Apr 1, 2006·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Maximilian FernandezGerald Spotts
Mar 21, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·U MartinowitzA Lubetsky
Sep 22, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·S Revel-VilkM L Rand
Apr 26, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A BatorovaUNKNOWN European Haemophilia Treatment Standardisation Board
Apr 26, 2012·British Journal of Haematology·P Vince JenkinsJames S O'Donnell
Jul 11, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A SrivastavaUNKNOWN Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia
May 7, 2013·Haematologica·Séverine HenrardCedric Hermans
Oct 3, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·E SantagostinoI Matytsina
Sep 6, 2017·Haemophilia : the Official Journal of the World Federation of Hemophilia·P A HolmeA Batorova

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Software Mentioned

Excel
PLA
JMP

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.